After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Claudin18.2 is out, but the US big pharma opts in to a new project.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
